Clinical Trial Update: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

AC176, an investigational therapy, in a Phase 1 study for metastatic castration-resistant prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• AC176 (AC176)

Snippet

Sponsor: Accutar Biotechnology Inc | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 1 | Status: TERMINATED